Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926
Recruiting
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Gender:
FEMALE
Ages:
Between 18 years and 60 years
Trial Updated:
06/04/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +1124 locations
Conditions: Breast Cancer
Register for Updates
TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)
NCT06137807
Recruiting
The TricValve® Transcatheter Bicaval Valve System is a bicaval transcatheter tricuspid valve replacement system, which includes the TricValve® Transcatheter Bicaval Valve for superior vena cava (SVC) and the TricValve® Transcatheter Bicaval Valve for inferior vena cava (IVC). The TricValve® Transcatheter Bicaval Valves are pre-mounted into the TricValve® Delivery System which is used for percutaneous access and delivery of the TricValve® Transcatheter Bicaval Valve in the vena cava. The system i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: St. Joseph's Hospital and Medical Center, Phoenix, Arizona +35 locations
Conditions: Tricuspid Regurgitation, Tricuspid Valve Disease
Register for Updates
Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer
NCT06356155
Recruiting
This trial is a multi-site, single-arm, phase 2 trial of neoadjuvant combination of enfortumab vedotin and pembrolizumab in cisplatin-eligible patients with high-grade localized/locally advanced cT1-4 N0-1 M0 upper tract urothelial cancer who are deemed eligible for curative-intent surgery (radical nephroureterectomy or distal ureterectomy) followed by adjuvant pembrolizumab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Conditions: Urothelial Carcinoma
Register for Updates
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
NCT06512883
Recruiting
The main purpose of study is to assess the safety, tolerability, and pharmacokinetic (PK) of benralizumab.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
06/04/2025
Locations: Research Site, Aurora, Colorado +5 locations
Conditions: Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Register for Updates
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
NCT06634589
Recruiting
The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This study is structured as a master protocol with separate substudies. This study currently includes four substudies, and more substudies may be added as other combination agents are identified.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Mayo Clinic Phoenix, Phoenix, Arizona +48 locations
Conditions: B-cell Malignancy, Relapsed Cancer, Refractory Cancer, B-cell Lymphoma
Register for Updates
Heterogeneity of Vascular Adaptations to Exercise With Aging in Women and Men
NCT06912984
Recruiting
The goal of the proposed study is to understand the reasons for the variability in aerobic exercise (AE) training benefits on the vasculature in middle-age and older (MA/O) adults, including differences between men and women. To achieve this goal, a mechanistic randomized controlled (RCT) will be conducted, in which adults are randomized to 12-weeks intervention of AE or no-exercise Control. Our overall hypothesis is that the exercise response variation in vascular benefits is related to age and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: University of Colorado Anschutz Medical Center, Clinical Translational Research Center and Exercise Research Laboratory, Aurora, Colorado
Conditions: Aging, Physical Activity, Vascular Health
Register for Updates
Vaginal Microbiome Seeding and Health Outcomes in Cesarean-delivered Neonates.
NCT03298334
Recruiting
Neonates delivered by scheduled Cesarean Section will be randomized to receive vaginal seeding (exposing the infant to Mother's vaginal flora) or sham. Infants will be followed for three years to examine health outcomes including microbiome development, immune development, metabolic outcomes, and any adverse events.
Gender:
ALL
Ages:
Between 0 days and 50 years
Trial Updated:
06/04/2025
Locations: Inova Health System, Falls Church, Virginia
Conditions: Cesarean Delivery Affecting Newborn, Obesity, Childhood, Intestinal Microbiome, Microbiota, Host Microbial Interactions, Gastrointestinal Microbiome
Register for Updates
Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and OU Relapse in Veterans
NCT04360681
Recruiting
The overall objective of the proposed study is to determine if lofexidine (LFX) as an adjunct to buprenorphine (BUP) treatment improves symptoms of both opioid use disorder (OUD) and Post-Traumatic Stress Disorder (PTSD). Other study objectives are to compare the safety, tolerability, and efficacy of BUP treatment alone, to BUP treatment with adjunct LFX, on measures of OUD and PTSD symptoms in Veterans with both prognosis .
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/04/2025
Locations: Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas +1 locations
Conditions: Post Traumatic Stress Disorder, Opioid-use Disorder
Register for Updates
Data Collection Study of Pediatric and Adolescent Gynecology Conditions
NCT04717349
Recruiting
Background: Gynecologic conditions are those that are related to the reproductive system. They can be reproductive gland disorders or reproductive system tumors. They can also be inborn anomalies of the reproductive tract. Researchers want to gather data over time from a large group of young people with these conditions. Objective: To create a database about child and teenage gynecologic conditions. Eligibility: Participants of any age with known or suspected pediatric and adolescent gyneco... Read More
Gender:
ALL
Ages:
Between 1 day and 100 years
Trial Updated:
06/04/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Disorders of Sex Development (DSD), Pediatric and Adolescent Cancers of the Genital Tract, Reproductive Endocrine Conditions in Puberty, Structural Gynecologic Conditions Including Vulvar and Vaginal Conditions
Register for Updates
Conversations You Want About Corona Virus Disease (COVID-19)
NCT05191420
Recruiting
Web-enabled virtual topical guide: develop virtual conversations for each concern and intensity level
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Wake Forest Health Sciences, Winston-Salem, North Carolina
Conditions: Covid19
Register for Updates
XTX301 in Patients With Advanced Solid Tumors
NCT05684965
Recruiting
This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: University of California, Davis Comprehensive Cancer Center, Sacramento, California +10 locations
Conditions: Advanced Solid Tumor
Register for Updates
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05894239
Recruiting
This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance therapy, after induction therapy in participants with previously untreated HER2-positive advanced breast cancer (ABC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Banner Health MD Anderson AZ, Gilbert, Arizona +168 locations
Conditions: Metastatic Breast Cancer
Register for Updates